EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Immune Landscape of Acral Melanoma: From Basic to Clinical

Lihong Jiang iD, Zhaotian Zhang

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71615 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 04.05.2026. Verfasst von Lihong Jiang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, School…. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Skin Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acral melanoma (AM) is an aggressive melanoma subtype with poor prognosis and limited response to immune checkpoint inhibitors (ICIs). Despite increasing research efforts, the mechanisms underlying therapeutic resistance remain incompletely understood.

Aim

This review examines the mechanisms driving immunotherapy resistance in AM, summarizes current clinical advances in combination regimens, and explores future therapeutic directions.

Methods

A narrative review of recent literature was undertaken, encompassing studies on resistance mechanisms and clinical trials investigating novel ICI‐based combination therapies for AM.

Results

AM exhibits distinct immunosuppressive microenvironment characterized by low tumor mutational burden, reduced CD8+ T‐cell infiltration, enrichment of regulatory T cells, and specific genetic alterations. Emerging clinical data demonstrate that combination regimens—particularly dual ICIs (anti‐PD‐1 plus anti‐CTLA‐4) and ICI combinations with anti‐angiogenic agents or chemotherapy—have shown promising efficacy, with some achieving superior response rates in AM patients.

Discussion

Understanding resistance mechanisms is critical for identifying novel therapeutic targets and optimizing personalized strategies. Current evidence suggests combination therapies may overcome resistance and improve outcomes, though optimal regimens and sequencing require further investigation.

Conclusion

Continued research into innovative combination approaches and predictive biomarkers is urgently needed to improve survival in AM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaImmune Checkpoint InhibitorsSkin NeoplasmsHumansTumor MicroenvironmentDrug Resistance, NeoplasmImmunotherapyAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

acral melanomacombination regimendrug resistanceimmune checkpointimmunotherapy

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
  • State Key Laboratory of Transvascular Implantation Devices, Hangzhou, China.

ORCID-Profile: Lihong Jiang

Zitieren

APA

Jiang, L., & Zhang, Z. (2026). The Immune Landscape of Acral Melanoma: From Basic to Clinical. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71615

Vancouver

Jiang L, Zhang Z. The Immune Landscape of Acral Melanoma: From Basic to Clinical. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71615

BibTeX
@article{Jiang2026,
  author = {Jiang, Lihong and Zhang, Zhaotian},
  title = {The Immune Landscape of Acral Melanoma: From Basic to Clinical},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71615}
}
Kostenlos starten →